30 August 2024 Inhalation
21. Trends in the Prevalence of Chronic Obstructive
Pulmonary Disease Among Adults Aged ≥ 18 Years
— United States, Y Liu, S Carlson, K Watson, F Xu,
K Greenlund, 2011-2021, CDC Weekly, November
17, 2023, 72(46);1250-1256. https://www.cdc.gov/
mmwr/volumes/72/wr/mm7246a1.htm.
22. CDC, Data, Statistics, and Surveillance.
https://www.cdc.gov/asthma/asthmadata.htm#:~:
t e x t=T h e % 2 0 c u r r e n t % 2 0 a s t h m a% 2 0 p r e v a
lence%20a mong,signif ica ntly %20to%206.5%
25%20in%202021.
23. Referencing Approved Drug Products in ANDA
Submissions, Guidance for Industry. https://www.
fda.gov/media/102360/download.
24. Deconstructing Genus Medical Technologies,
LLC, v. FDA: A Misunderstood Court Decision.
https://www.ebgadvisors.com/insights/publications/
deconstructing-genus-medical-technologies- llc-v-fda-
a-misunderstood-court-decision-continues-to-sow-
confusion-and-may-prompt-congressional-action.
25. 21CFR 314.54(a): Part 314 - Applications for
FDA Approval to Market a New Drug. https://
www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/
CFRSearch.cfm?fr=314.54.
26. Draft Guidance on Albuterol Sulfate November
2023. November 2023. https://www.accessdata.fda.
gov/drugsatfda_docs/psg/PSG_020503.pdf.
27. U.S. Supply Chain Vulnerabilities and Resil-
ience. https://www.uscc.gov/sites/default/files/2022-
11/Chapter_2_Section_4--U.S._Supply_Chain_
Vulnerabilities_and_Resilience.pdf.
28. FTC Challenges More an 100 Patents as
Improperly Listed in the FDA's Orange Book.
https://www.ftc.gov/news-events/news/press-
releases/2023/11/ftc-challenges-more-100-patents-
improperly-listed-fdas-orange-book.
Rik Lostritto is an independent consultant, based in
Maitland, Florida, US, RTLostritto@gmail.com,
LinkedIn: Richard Lostritto.
9. orat S, Meshram S. Review on Quality by
Designing for Metered Dose Inhaler Product Devel-
opment. Sch Acad J Pharm, 2015; 4(6):324-330.
10. Stein S, iel C. e History of erapeutic
Aerosols: A Chronological Review. J Aerosol Med
Pulm Drug Deliv, 2017 Feb; 30(1):20-41.
11. Pritchard J. e Climate is Changing for
Metered-Dose Inhalers and Action is Needed. Drug
Des Devel er, 2020; 14:3043-3055.
12. Kontny MJ, Destefano G, Jager P, McNamara
D, Turi J, Van Campen L. Issues Surrounding MDI
Formulation Development with Non-CFC Propel-
lants. J Aerosol Med, 1991 Fall; 4(3):181-187.
13. 21CFR, Part 81.10(g), Termination of Pro-
visional Listing Of Color Additives.(g). https://
www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/
cfrsearch.cfm?fr=81.10.
14. CPG Sec 500.450 Volatile N-Nitrosamines
in Rubber Baby Bottle Nipples. https://www.fda.
gov/regulatory-information/search-fda-guidance-
documents/cpg-sec-500450-volatile-n- nitrosamines-
rubber-baby-bottle-nipples.
15. Perumal R, Leite M, van Zyl-Smit R. e Rela-
tionship Between Clinical Trial Participation and
Inhaler Technique Errors in Asthma and COPD
Patients. Int J Chron Obstruct Pulmon Dis, 2020
Jun 2; 15:1217-1224.
16. Tashkin D, Celli B, Decramer M, Liu D, Bur-
khart D, Cassino C, Kesten S. Bronchodilator
Responsiveness in Patients with COPD. Eur Respir
J, 2008; 31:742-750.
17. An Overview of In Vitro BE Studies, M. Javid-
nia, Division of Generic Drug Study Integrity, Office
of Study Integrity and Surveillance, Office of Trans-
lational Sciences CDER, US FDA Office of Study
Integrity and Surveillance (OSIS) Workshop 2022 -
July 19, 2022, slides 22, 23 and 24. https://www.fda.
gov/media/166004/download.
18. e Least Burdensome Provisions: Concept and
Principles 4 Guidance for Industry and Food and
Drug Administration Staff, https://www.fda.gov/
media/73188/download.
19. FDA Guidance: Submitting Separate Market-
ing Applications and Clinical Data for Purposes of
Assessing User Fees, 2005, https://www.fda.gov/
media/72397/download.
20. Referencing Approved Drug Products in ANDA
Submissions Guidance for Industry, 2020. https://
www.fda.gov/media/102360/download.
